Skip to content
Signal Bureau What’s happening · what the record shows

Pfizer

One of the world's largest pharmaceutical companies — vaccines, oncology, and the drug pipeline behind them.

Coverage of Pfizer is rising : 6 signals on the latest tracked day, up 50% from its three-week baseline of 4, across 3 domains (down from 4 a week ago). That makes it the #343 most-covered of the 348 concerns we track.

If Pfizer matters to your work, coverage is climbing off its baseline — worth a closer-than-usual look this week.

What’s changed

What the reporting says

Across 39 tracked stories from 16 outlets, reporting on Pfizer most often describes regulatory approvals (6), military action (1), treaties or agreements (1), launches or releases (1).

It shows up alongside Astrazeneca (18), Bristol Myers Squibb (19), Novartis (12), Regeneron (10), Gilead (11), Abstract (12), Eli Lilly (11), FDA (11).

Two steps out: Lung Cancer (through Astrazeneca, 13 shared stories on the weaker link); Catalyzex (through Abstract, 12 shared stories on the weaker link); Citations Loading (through Abstract, 12 shared stories on the weaker link); Citations Loading Bibliographic (through Abstract, 12 shared stories on the weaker link).

Tracked since Apr 12, with coverage on 18 separate days — concentrated in Society News and Biotech Pharma.

What the crowd is pricing

Coverage momentum and market odds are separate readings — one can move without the other. A price is what the crowd believes, shown as a signal, not a forecast of ours.
Ask the engine about Pfizer + Track Pfizer for a daily read
Counts computed from our committed signal record (Aug 4 – Sep 6, 8 tracked days). Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Sep 6, 9:21 AM PT